CD274 and non-small cell lung carcinoma: However, they did not examine the expression of PD-L1, the standard prognostic marker in anti-PD-1/L1 antibody treatment, and included driver gene alteration-positive NSCLC, which is less effective than anti-PD-1/L1 antibodies [17], which may cause a discrepancy in the results.